Adverse drug reactions to osteoporosis treatments

References

• Katz MD. Evaluation of adverse drug reactions. In: Decision Making in Medicine (3rd Edition). An Algorithmic Approach. Mushlin SB, Greene II HL (Eds.). Mosby Elsevier, PA, USA, 698–699 (2010).
   Google Scholar
• Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ329, 15–19 (2004).
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Reginster JY, Boonen S et al. Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int.89(2), 91–104 (2011).
   PubMed Web of Science ®Google Scholar
• Sambrook P, Cooper C. Osteoporosis. Lancet367, 2010–2018 (2006).
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet348, 1535–1541 (1996).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA280, 2077–2082 (1998).
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA282, 1344–1352 (1999).
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int.11, 83–91 (2000).
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med.344, 333–340 (2001).
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res.19, 1241–1249 (2004).
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356, 1809–1822 (2007).
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, MacClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med.361, 756–765 (2009).
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA282, 637–645 (1999).
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner. Res.20, 1514–1524 (2005).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD et al. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med.362, 686–696 (2010).
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J. Bone Miner. Res.23, 1923–1934 (2008).
   PubMed Web of Science ®Google Scholar
• Archer DF, Pinkerton JV, Utian WH et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause16, 1109–1115 (2009).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med.350, 459–468 (2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab.90, 2816–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med.344, 1434–1441 (2001).
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med.146, 326–339 (2007).
   PubMed Web of Science ®Google Scholar
• Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo. Clin. Proc.84, 632–637 (2009).
   PubMed Web of Science ®Google Scholar
• Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. Curr. Opin. Rheumatol.21, 363–368 (2009).
   PubMed Web of Science ®Google Scholar
• Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug. Saf.30, 755–763 (2007).
   PubMed Web of Science ®Google Scholar
• Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am. J. Med.122, S22–S32 (2009).
   PubMed Web of Science ®Google Scholar
• Watts NB, Diab DL. Long-term use of bisphosphosphonates in osteoporosis. J. Clin. Endocrinol. Metab.95, 1555–1565 (2010).
   PubMed Web of Science ®Google Scholar
• Papapetrou PD. Bisphosphonate-associated adverse events. Hormones8, 96–110 (2009).
   PubMedGoogle Scholar
• Abrahamsen B. Adverse effects of bisphosphonates. Calcif. Tissue Int.86, 421–435 (2010).
   PubMed Web of Science ®Google Scholar
• Rizzoli R. Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM104, 281–300 (2011).
   PubMedGoogle Scholar
• Coleman RE. Risks and benefits of bisphosphonates. Br. J. Cancer98, 1736–1740 (2008).
   PubMed Web of Science ®Google Scholar
• Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo. Clin. Proc.77, 1031–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ341, c4444 (2010).
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA304, 657–663 (2010).
   PubMed Web of Science ®Google Scholar
• Dixon WG, Solomon DH. Bisphosphonates and esophageal cancer-a pathway through the confusion. Nat. Rev. Rheumatol.7(6), 369–372 (2011).
   PubMedGoogle Scholar
• Bilezikian J, Klemes A, Siris E. Esophageal cancer reports coincident with risedronate use. J. Bone Miner. Res.24(Suppl. 1), A09001305 (2009) (Abstract).
   Google Scholar
• Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N. Engl. J. Med.360, 89–90 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro. J. Bone Miner. Res.19, 278–288 (2004).
   PubMed Web of Science ®Google Scholar
• Bock O, Boerst H, Thomasius FE et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J. Musculoskelet. Neuronal. Interact.7, 144–148 (2007).
   PubMedGoogle Scholar
• Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet. Disord.10, 113 (2009).
   PubMed Web of Science ®Google Scholar
• Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J. Bone Miner. Res.25, 2–10 (2010).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N. Engl. J. Med.356, 1895–1896 (2007).
   PubMed Web of Science ®Google Scholar
• Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med.168, 826–831 (2008).
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Christensen S, Mehnert F et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case–control study. BMJ336, 813–816 (2008).
   PubMed Web of Science ®Google Scholar
• Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma22, 346–350 (2008).
   PubMed Web of Science ®Google Scholar
• Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin. Endocrinol.72, 161–168 (2010).
   PubMed Web of Science ®Google Scholar
• Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf.32, 775–785 (2009).
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Akesson K, Bouxsein M et al. Subtrochanteric fracture after long-term treatment with bisphosphonates. Osteoporos. Int.22, 373–390 (2011).
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res.25, 2267–2294 (2010).
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J Med.364, 1728–1737 (2011).
   PubMed Web of Science ®Google Scholar
• Lenart BA, Neviaser AS, Lyman S et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos. Int.20, 1353–1362 (2009).
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MP, Genant HK et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med.362, 1761–1771 (2010).
   PubMed Web of Science ®Google Scholar
• Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos. Int.21, 723–732 (2010).
   PubMed Web of Science ®Google Scholar
• Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol.7, 508–514 (2006).
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Burlet N, Cahall D et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone42, 841–847 (2008).
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res.22, 1479–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Cooper C, Steinbuch M, Stevenson R, Miday R, Watts NB. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos. Int.24, 569–577 (2010).
   Google Scholar
• Khan A. Osteonecrosis of the jaw and bisphosphonates. BMJ340, c246 (2010).
   Google Scholar
• Grbic JT, Landesberg R, Lin SQ et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J. Am. Dent. Assoc.139, 32–40 (2008).
   PubMed Web of Science ®Google Scholar
• Lesclous P, Abi NS, Carrel JP et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone45, 843–852 (2009).
   PubMed Web of Science ®Google Scholar
• Boonen S, Sellmeyer DE, Lippuner K et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int.74, 641–648 (2008).
   PubMed Web of Science ®Google Scholar
• Miller PD, Leigh C, Ward P. Renal tolerability of intravenous ibandronate allow administration by short injection. Ann. Rheum. Dis.65(Suppl. 1), FR10455 (2006).
   Google Scholar
• Smith MR, Egerdie B, Hernandez TN et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med.361, 745–755 (2009).
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Toulis KA, Goulis DG et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm. Metab. Res.41, 721–729 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos. Int.22, 435–446 (2011).
   PubMed Web of Science ®Google Scholar
• Joshi PA, JAckson HW, Beristain AG et al. Progesterone induces adult mammary stem cell expansion. Nature465, 803–807 (2010).
   PubMed Web of Science ®Google Scholar
• Schramek D, Leibbrandt A, Sigl V et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature468, 98–102 (2010).
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Toulis KA. Denosumab-related osteonecrosis of the jaws. Osteoporos. Int.22, 369–370 (2011).
   PubMed Web of Science ®Google Scholar
• Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br. J. Oral. Maxillofac. Surg.48, 221–223 (2010).
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol.28, 5132–5139 (2010).
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Man Z, Mellstrom D et al. Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension. OC24. Osteoporos. Int.22(Suppl. 1), S107 (2011).
   Google Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295, 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Mosca L, Barrett-Connor E, Wenger NK et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol.88, 392–395 (2001).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med.355, 125–137 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas34, 65–73 (2000).
   PubMed Web of Science ®Google Scholar
• Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr. Med. Res. Opin.21, 1441–1452 (2005).
   PubMed Web of Science ®Google Scholar
• Clemett D, Spencer CM. Raloxifene: A review of its use in postmenopausal osteoporosis. Drugs60, 379–411 (2000).
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Moscarelli E et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet. Gynecol.104, 837–844 (2004).
   PubMed Web of Science ®Google Scholar
• Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause12, 444–452 (2005).
   PubMed Web of Science ®Google Scholar
• De Villiers TJ, Kendler DL, Chines A et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled Phase 3 trial. Osteoporos. Int.22(2), 567–576 (2011).
   PubMed Web of Science ®Google Scholar
• Mosca L, Grady D, Barrett-Connor E et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke40, 147–155 (2009).
   PubMed Web of Science ®Google Scholar
• Ensrud K, Genazzani AR, Geiger MJ et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am. J. Cardiol.97, 520–527 (2006).
   PubMed Web of Science ®Google Scholar
• Yaffe K, Krueger K, Cummings SR et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am. J. Psychiatry162, 683–690 (2005).
   PubMed Web of Science ®Google Scholar
• Jolly EE, Bjarnason NH, Neven P et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause10, 337–344 (2003).
   PubMed Web of Science ®Google Scholar
• Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J. Thromb. Haemost.5, 692–699 (2007).
   PubMed Web of Science ®Google Scholar
• Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb. Haemost.83, 657–660 (2000).
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch. Intern. Med.158, 585–593 (1998).
   PubMed Web of Science ®Google Scholar
• Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos. Int.21, 1181–1187 (2010).
   PubMed Web of Science ®Google Scholar
• Perrio M, Wilton L, Shakir S. Analysis of venous thromboembolism in the strontium ranelate prescription-event monitoring (PEM) cohort: interim results. Drug Saf.31, 1 (2008).
   PubMedGoogle Scholar
• Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs68, 2709–2737 (2008).
   PubMed Web of Science ®Google Scholar
• Deal C, Omizo M, Schwartz EN et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res.20, 1905–1911 (2005).
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol. Pathol.32, 426–438 (2004).
   PubMed Web of Science ®Google Scholar
• Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J. Bone Miner. Res.22, 334 (2007).
   PubMed Web of Science ®Google Scholar
• Berry DC, Knapp P, Raynor DK. Provision of information about drug side-effects to patients. Lancet359, 853–854 (2002).
   PubMed Web of Science ®Google Scholar
• Berry DC, Raynor DK, Knapp P, Bersellini E. Patients’ understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf.26, 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Arimone Y, Miremont-Salame G, Haramburu F et al. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br. J. Clin. Pharmacol.64, 482–488 (2007).
   PubMedGoogle Scholar
• Harmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur. J. Clin. Pharmacol.64, 743–752 (2008).
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM. Difficulties in assessing adverse drug reactions in clinical trials. Prog. Neuropsychopharmacol. Biol. Psychiatry6, 651–657 (1982).
   PubMedGoogle Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet356, 1255–1259 (2000).
   PubMed Web of Science ®Google Scholar
• Doherty MJ. Algorithms for assessing the probablity of an adverse drug reaction. Respiratory Medicine CME2, 63–67 (2009).
   Google Scholar
• Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet377, 1276–1287 (2011).
   PubMed Web of Science ®Google Scholar